- The approval is based on P-I/III IMpower133 study assessing Tecentriq (1200mg, IV,) + CT (carboplatin and etoposide) q3w over 60mins., if tolerated subsequent infusion can be administered over 30mis. vs CT as monothx. in patients with extensive-stage small-cell lung cancer
- The P-I/III IMpower133 study results: median OS (12.3 vs 10.3mos.); m-PFS (5.2 vs 4.3mos.); safety profile was consistent with the previous study; no new safety signals is observed
- Tecentriq (atezolizumab) is a mAb targeting PD-L1, blocking its interaction with PD-1 and B7.1 receptor and becomes the new therapy option for patients with extensive-stage SCLC in 17yrs.
Click here to read full press release/ article | Ref: Chugai Pharmaceutical | Image: Behance